ZNF667 Antibody - BSA Free

Western Blot: ZNF667 Antibody - BSA Free [NBP1-77357] -

ZNF667 and ZNF667-AS1 as novel markers for prognosis in PDAC.a Immunohistochemistry of ZNF667 shows variations of abundance across patients using the tissue microarray analysis. b Overall survival and progression-free survival of self-collected PDAC patients grouped by the abundance of ZNF667. c Relative abundance of ZNF667 and ZNF667-AS1 to ACTB mRNA in normal pancreas cells (HPDE6-C7), human embryonic kidney cells (HEK293T), liver metastasis pancreas cancer cells (L3.7), and the pancreas cancer cells detected by RT-qPCR. All pancreas cancer cells showed a decreased level of ZNF667 and ZNF667-AS1. *P < 0.05; **P < 0.01. d Immunoblot showing the decreased abundance of ZNF667 in multiple pancreas cancer cell lines. The abundance was calculated at the bottom. e, f Validation of ZNF667 and ZNF667-AS1 overexpression (OE) in two pancreas cancer cell lines. **P < 0.01; ****P < 0.0001. g Immunoblot showing the abundance of ZNF667 in PANC-1 and SW1990 cells before and after overexpression. h, i Proliferation evaluation (CCK8-positive cell ratio) after ZNF667 and ZNF667-AS1 overexpression in two pancreas cancer cell lines. n = 3 for each time point. **P < 0.001; ****P < 0.00001. j Evaluation of cellular apoptosis after ZNF667-AS1 overexpression in two pancreas cancer cell lines. n.s., no significance. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/35165277), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: ZNF667 Antibody - BSA Free [NBP1-77357] -

ZNF667 and ZNF667-AS1 as novel markers for prognosis in PDAC.a Immunohistochemistry of ZNF667 shows variations of abundance across patients using the tissue microarray analysis. b Overall survival and progression-free survival of self-collected PDAC patients grouped by the abundance of ZNF667. c Relative abundance of ZNF667 and ZNF667-AS1 to ACTB mRNA in normal pancreas cells (HPDE6-C7), human embryonic kidney cells (HEK293T), liver metastasis pancreas cancer cells (L3.7), and the pancreas cancer cells detected by RT-qPCR. All pancreas cancer cells showed a decreased level of ZNF667 and ZNF667-AS1. *P < 0.05; **P < 0.01. d Immunoblot showing the decreased abundance of ZNF667 in multiple pancreas cancer cell lines. The abundance was calculated at the bottom. e, f Validation of ZNF667 and ZNF667-AS1 overexpression (OE) in two pancreas cancer cell lines. **P < 0.01; ****P < 0.0001. g Immunoblot showing the abundance of ZNF667 in PANC-1 and SW1990 cells before and after overexpression. h, i Proliferation evaluation (CCK8-positive cell ratio) after ZNF667 and ZNF667-AS1 overexpression in two pancreas cancer cell lines. n = 3 for each time point. **P < 0.001; ****P < 0.00001. j Evaluation of cellular apoptosis after ZNF667-AS1 overexpression in two pancreas cancer cell lines. n.s., no significance. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/35165277), licensed under a CC-BY license. Not internally tested by Novus Biologicals.